Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for
BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2
diabetes mellitus and insufficient glycaemic control.